File

NextMart, Inc. - Audited Financial Statements and Up Listing

Retrieved on: 
Thursday, October 20, 2022
Disclosure, Risk management, Risk, SEC, Mission statement, Audit, Private Securities Litigation Reform Act, Pink sheet, Goal, Company, Acquisition, Industry, CEO, Nature, FINRA, FYE, File, Common stock, OTCQB, Delaware General Corporation Law, OTC Markets Group, Security (finance)

Upon approval of the Form 211, the Company will make the appropriate application with OTC Markets to up list to the OTCQB.

Key Points: 
  • Upon approval of the Form 211, the Company will make the appropriate application with OTC Markets to up list to the OTCQB.
  • Kathryn Gavin (CEO of the Company), states" We have been working to complete the Audit now for over four months.
  • Certain statements that we make may constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995.
  • These forward-looking statements are, by their nature, subject to significant risks and uncertainties.

Juva Life Successfully Scales Novel Compound JUVA-041 for Preclinical Studies and Eventual Commercialization, Highlighting Successful Chemistry Process

Retrieved on: 
Monday, October 17, 2022
Pharmacology, Cannabis, BOARD, Efficiency, IND, Cytokine, THE, Inflammation, Company, Learning, Pharmacy, Founder, CSE, Toxicity, CEO, Face, File, GLOBE, FDA, Pharmaceutical industry

The Companys approach through its proprietary platform is proving to be successful, showcasing superior medicinal chemistry, and a large commercial advantage.

Key Points: 
  • The Companys approach through its proprietary platform is proving to be successful, showcasing superior medicinal chemistry, and a large commercial advantage.
  • Novel compound Juva-041 has demonstrated potent anti-inflammatory properties in phenotypic assays of inflammation, and is now being scaled up to support pre-clinical studies, said Doug Chloupek, CEO and Founder of Juva.
  • Juva has discovered novel compounds JUVA-019 and JUVA-041 that have shown superior anti-inflammatory drug properties compared to many commercially available products.
  • JUVA-041 has a pending patent filed by Juva Life and was identified by Juvas chemistry researcher through a chemocentric approach to bioactive identifications.

Tax Tip - Small Business Week 2022: the CRA is here year-round to help small businesses with their unique needs

Retrieved on: 
Monday, October 17, 2022
ED, Client, By-election, Growth, Income tax, Self-assessment, CRA, Science, Investor, Income, EFILE, SR, Research, Program, R, Software, Goal, Canada Revenue Agency, SALT, Government of Canada, SERS, Agency, GST, Small business, Internet, Corporation, File, Government, COVID-19, CDA, Renewable energy, Cryptocurrency, Online shopping, Tutoring

Here are some new and existing CRA services that can support you and your small business now and in the future.

Key Points: 
  • Here are some new and existing CRA services that can support you and your small business now and in the future.
  • The CRA has taken another step to ensure that your tax information is secure and to guard against unauthorized access.
  • By accessing My Business Account you or your delegated authority can quickly and easily verify new authorized representatives and ensure that your tax information is secure.
  • Read about how the SR&ED tax incentives help businesses grow and reach their goals at Scientific, Research and Experimental Development Success Stories .

Nuwellis Announces Pricing of $9.6 Million Upsized Underwritten Public Offering

Retrieved on: 
Friday, October 14, 2022
Classes of United States senators, U.S. Securities and Exchange Commission, Sale, Hospital, SEC, SEC filing, Growth, Ladenburg Thalmann, Science, Patient, Fifth Avenue, Private Securities Litigation Reform Act, Company, Exercise, Overload, Hypervolemia, Form, Series, Adult, File, GLOBE, 4th floor, Prospectus, Forward-looking statement, COVID-19, Diuretic, Security (finance), Nasdaq

MINNEAPOLIS, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (Nuwellis or the Company), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the pricing of an underwritten public offering of units for gross proceeds of approximately $9.6 million prior to deducting underwriting discounts and commissions and offering expenses payable by Nuwellis.

Key Points: 
  • MINNEAPOLIS, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (Nuwellis or the Company), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the pricing of an underwritten public offering of units for gross proceeds of approximately $9.6 million prior to deducting underwriting discounts and commissions and offering expenses payable by Nuwellis.
  • Ladenburg Thalmann & Co. Inc. is acting as sole book-running manager in connection with the offering.
  • The conversion price of the preferred stock issued in the transaction is fixed and does not contain any variable pricing feature or any price-based anti-dilutive feature.
  • A final prospectus relating to this offering will be filed by Nuwellis with the SEC.

LEADING EDGE MATERIALS APPROVES CONTRACTOR TO OPEN BIHOR SUD ADITS

Retrieved on: 
Thursday, October 13, 2022
News, U, Union, Lead, Nickel, RMM, Regulation and licensure in engineering, License, Miner, Nasdaq, Knowledge, FRA, Mining, Ministry of Energy (Petroleum Division), Board, CEO, Cobalt, Copper, Gold, File, Feasibility study, Director, Ministry, Forestry, Ownership, Uranium, Consultant, SEDAR, Rare-earth element, Project, Company

In addition, RMM has detailed knowledge of the Project and historic mining works within the area.

Key Points: 
  • In addition, RMM has detailed knowledge of the Project and historic mining works within the area.
  • (see attached images)
    The Bihor Sud exploration license perimeter covers a 25 square kilometer area in the Northern Apuseni Mountains of Transylvania.
  • The Project is developed by Leading Edge Materials through its 51% owned local Romanian joint-venture subsidiary, LEM Romania SRL (LEMR), with a local Romanian arms length part owning the residual 49%.
  • Martin S. Oczlon, PhD Geo, CEng MIMMM, a consultant to Leading Edge Materials and Qualified Person as defined in NI 43-101, has reviewed and verified the technical content of this press release.

LOTTERY.COM DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Lottery.com, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, October 15, 2022
Legal, Professional Services, News, Sale, Telephone, SEC, Person, NASDAQ, Complaint, Jeanne Eagels, Court, Company, District court, Board, Wind, File, P.C, Compliance, Security (finance), Renewable energy

Investors have until October 18, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until October 18, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Accordingly, on June 30, 2022, the Board terminated the Companys President, Treasurer, and Chief Financial Officer Ryan Dickinson.
  • On this news, Lottery.coms stock price fell $0.15 per share, or more than 12%, to close at $1.07 per share on July 6, 2022.
  • Then, on July 15, 2022, Lottery.com announced that Chief Revenue Officer Matthew Clemenson had resigned on July 11, 2022, effective immediately.

Axcella Therapeutics to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference

Retrieved on: 
Friday, October 14, 2022
Health, Diabetes, Clinical Trials, General Health, Pharmaceutical, Biotechnology, U.S. Securities and Exchange Commission, EMM, Securities Act of 1933, Webcast, Regulation Fair Disclosure, Investor, Review, IND, Security (finance), NASH, FAQ, Regulation, Emms, File, Homeostasis, Disclosure, Pharmaceutical industry

An archive of the webcast replay will be available on the Companys website for up to 90 days.

Key Points: 
  • An archive of the webcast replay will be available on the Companys website for up to 90 days.
  • Such disclosures include, but may not be limited to, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, and public conference calls and webcasts.
  • Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs).
  • Axcellas pipeline includes lead therapeutic candidates in Phase 2 development for the treatment of Long COVID and NASH.

Gatos Silver Provides Bi-weekly Status Report and Announces NYSE’s Grant of Trading Extension

Retrieved on: 
Friday, October 14, 2022
Natural Resources, Other Manufacturing, Manufacturing, Mining, Minerals, News, U.S. Securities and Exchange Commission, National instrument, Form 10-Q, Originality, SEC, Mission statement, Review, Silver, Toronto Stock Exchange, NYSE, National, Mineral resource estimation, Annual report, KPMG, Ontario Securities Commission, NP, Form 10-K, Notice, Company, KPMG LLP, National Instrument 43-101, File, Life, Failure, LLP, Organization, Online gambling, Audit

Gatos Silver, Inc. (NYSE/TSX: GATO) (Gatos Silver or the Company) is providing this bi-weekly default status report in accordance with National Policy 12-203 - Management Cease Trade Orders (NP 12-203).

Key Points: 
  • Gatos Silver, Inc. (NYSE/TSX: GATO) (Gatos Silver or the Company) is providing this bi-weekly default status report in accordance with National Policy 12-203 - Management Cease Trade Orders (NP 12-203).
  • On October 11, 2022, the Company announced quarterly production results for the third quarter of 2022 and updated production and cost guidance for 2022.
  • In addition, if the Company does not file its required SEC filings by April 15, 2023, the NYSE will initiate suspension and delisting procedures.
  • Gatos Silver is a silver dominant exploration, development and production company that discovered a new silver and zinc-rich mineral district in southern Chihuahua State, Mexico.

Prestige Biopharma Submitted Pre-BLA Type 4 Meeting Request to FDA for Herceptin Biosimilar

Retrieved on: 
Friday, October 14, 2022
Oncology, FDA, Health, Other Health, Pharmaceutical, Biotechnology, European Medicines Agency, NDS, Growth, Review, Marketing Authorisation Application, EMA, Trastuzumab, Regulation of tobacco by the U.S. Food and Drug Administration, Patient, Biosimilar, Health Canada, HER2, BPD, CEO, BLA, Breast, File, FDA, MAA, Generic drug, Pharmaceutical industry, Food

Prestige Biopharma Limited, a Singapore-based biopharmaceutical company, has submitted a request to the U.S. Food and Drug Administration (FDA) for a pre-submission meeting to discuss the companys planned Biologics License Application (BLA) for its Herceptin Biosimilar, HD201(Tuznue).

Key Points: 
  • Prestige Biopharma Limited, a Singapore-based biopharmaceutical company, has submitted a request to the U.S. Food and Drug Administration (FDA) for a pre-submission meeting to discuss the companys planned Biologics License Application (BLA) for its Herceptin Biosimilar, HD201(Tuznue).
  • The Biosimilar Biological Product Development (BPD) Type 4 Meeting is to discuss the format and content of a BLA in advance of the final submission.
  • The company will discuss the overall development program of HD201 with the FDA to identify potential filing and review issues.
  • Lisa Park, CEO of Prestige Biopharma, commented: This Type 4 Meeting will be the final gate of BLA submission for HD201.

CoStar Group Acquires Fairmas Benchmarking, a Leading Hospitality Benchmarking Product in Germany

Retrieved on: 
Thursday, October 13, 2022
Commercial Building & Real Estate, Technology, Construction & Property, Professional Services, Internet, Data Analytics, Lodging, Data Management, Travel, News, U.S. Securities and Exchange Commission, Risk, SEC, Workflow, NASDAQ, Homes.com, Research, CoStar Group, Security (finance), Data management, Benchmarking, Acquisition, Marketing, Industry, File, Database, STR, LoopNet, Solution, Property management

CoStar Group, Inc. (NASDAQ: CSGP), a leading provider of online real estate marketplaces, information and analytics in the commercial and residential property markets, announced today that it has acquired Fairmas Benchmarking, a leading German hospitality benchmarking product, from Fairmas GmbH.

Key Points: 
  • CoStar Group, Inc. (NASDAQ: CSGP), a leading provider of online real estate marketplaces, information and analytics in the commercial and residential property markets, announced today that it has acquired Fairmas Benchmarking, a leading German hospitality benchmarking product, from Fairmas GmbH.
  • The acquisition, which was completed on 10 October 2022, is an important addition to STR, CoStar Groups hospitality information and benchmarking business.
  • The expansion of our STR business in Germany is another important example of our strategic expansion of CoStar Group internationally, said Andrew Florance, Founder and Chief Executive Officer of CoStar Group.
  • We are very confident that STR and CoStar Group will take diligent care of our benchmarking customers in Germany, said Niels Schrder, Managing Director of Fairmas GmbH.